What Is SLU-PP-332?
SLU-PP-332 is a first-in-class synthetic pan-agonist of estrogen-related receptors (ERRα, ERRβ, ERRγ) developed by researchers at Saint Louis University. It activates all three ERR isoforms simultaneously, triggering transcriptional programs that closely mimic the metabolic adaptations induced by endurance exercise — particularly mitochondrial biogenesis, fatty acid oxidation, and oxidative muscle fiber transformation. For this reason SLU-PP-332 is frequently described as an “exercise mimetic” in the research literature.
A landmark 2023 Nature Communications paper demonstrated that SLU-PP-332 significantly improved aerobic capacity in sedentary mice without any physical training, reduced obesity-related metabolic dysfunction, and extended lifespan in aged mice. These findings generated widespread research interest and substantially increased demand for the compound.
Mechanism of Action
- ERRα/β/γ Pan-Agonism: Directly binds and activates all three estrogen-related receptors, nuclear transcription factors that regulate mitochondrial and metabolic gene expression
- PGC-1α Co-activation: ERR activation recruits PGC-1α (the master regulator of mitochondrial biogenesis), initiating a cascade that increases mitochondrial number and respiratory capacity
- OXPHOS Gene Upregulation: Increases expression of genes encoding ETC complexes I–V, dramatically improving cellular ATP production capacity
- Fiber Type Switching: Promotes transition from glycolytic (Type IIb) to oxidative (Type I/IIa) muscle fibers, the hallmark of endurance training adaptation
- Fatty Acid Oxidation: Upregulates carnitine palmitoyltransferase (CPT1), HADHA, and other beta-oxidation enzymes, shifting energy substrate preference toward fat
- VO₂max Surrogate: In animal models, SLU-PP-332 increases markers equivalent to maximal oxygen uptake capacity without exercise
Key Research Data
2023 Nature Communications Study
- Sedentary mice treated with SLU-PP-332 ran ~70% further in treadmill tests vs. untreated controls
- Significant increases in oxidative muscle fiber proportion (Type I and IIa)
- Improved insulin sensitivity and reduced visceral fat accumulation in diet-induced obesity model
- Extended median lifespan in aged C57BL/6J mice (18% increase)
Metabolic Disease Models
- Reduced hepatic steatosis (liver fat) in high-fat diet models
- Improved glucose tolerance and insulin signaling in obese mice
- Reduced body weight gain without food restriction
Cardiac Research
- Improved cardiac mitochondrial density and respiratory function in aging heart models
- Reduced fibrosis markers in pressure overload cardiac models
SLU-PP-332 vs. Other Exercise Mimetics
| Compound | Target | Primary Effect | Research Stage |
|---|---|---|---|
| SLU-PP-332 | ERRα/β/γ (pan) | Mitochondrial biogenesis, endurance | Preclinical |
| AICAR | AMPK activator | Fatty acid oxidation, endurance | Preclinical |
| GW501516 (Cardarine) | PPARδ agonist | Fatty acid oxidation | Discontinued (carcinogenicity) |
| SR9009 | Rev-erbα agonist | Circadian metabolic regulation | Preclinical |

HPLC Verified
Research Disclaimer: This product is sold strictly for in vitro research and laboratory use only. Not for human consumption. Not medical advice.